Peer reviewed articles

Preller KH, Schilbach L, Pokorny T, Flemming J, Seifritz E, Vollenweider FX (2018): Role of the 5-HT2A receptor in self- and other-initiated social interaction in LSD-induced states - a pharmacological fMRI study, J. Neuoscience (in press)

Kraehenmann R, Pokorny D, Aicher H. Preller KH, Pokorny T, Bosch O.G., Seifritz E., Vollenweider FX (2017): LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. Front Pharmacol. 2017 Nov 8;8:814. doi: 10.3389/fphar.2017.00814. eCollection 2017.

Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX (2017): Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic tonal structure in music. Cereb Cortex. 2017 Sep 28:1-12. doi: 10.1093/cercor/bhx257. [Epub ahead of print].

Preller KH, Burt JB, Ji JL, Schleifer C, Adkinson B, Stämpfli P, Repovs G, Krystal JH, Murray JD, Vollenweider FX, Anticevic A. (2017): Changes in resting-state global brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. bioRxiv 219956; doi:

Lewis C, Preller KH, Kraehenmann R, Michels L, Stämpfli P, Vollenweider FX (2017): Two dose investigation of the 5-HT-agonist psilocybin on regional and global cerebral blood flow. Neuroimage. 2017 Oct 1;159:70-78. doi:10.1016/j.neuroimage. 2017.07.020. Epub 2017 Jul 12.

Erraum to: Phenomenology, Structure, and Dynamic of Psychedelic States (2017): Phenomenology, Structure, and Dynamic of Psychedelic States. Curr Top Behav Neurosci. 2017 Jul 15. doi: 10.1007/7854_2017_477. [Epub ahead of print]

Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, Vollenweider FX (2017): Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology, 234:2031-46

Von Rotz Robin, Kometer Michael, Dornbierer Dario, Gertsch Jürg, Gachet Salomé M., Vollenweider FX, Seifritz Erich, Bosch Oliver G., Quednow Boris B., (2017): Neuronal oscillations and synchronicity associated with gamma-hydroxybutyrate during resting-state in healthy, male volunteers, Psychopharmacology, 234(13):1957-1968
Pokorny T, Preller KH, Kometer M, Dziobek I, Vollenweider FX (2017): Effect of psilocybin on empathy and moral decision-making. Int J Neuropsychopharmacol, 20:747-757

Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, Liechti ME, Seifritz E, Vollenweider FX (2017): The Fabric of Meaning and Subjective Effects in LSD-Induced States Depend on Serotonin 2A Receptor Activation, Curr Biol., 27(3):451-457

Preller KH, Pokorny T, Hock A, Kraehenmann R, Stämpfli P, Seifritz E, Scheidegger M,  Vollenweider FX (2016): Effects of serotonin 2A/1A receptor stimulation on social exclusion processing, PNAS, 113(18): 5119-5124

Preller KH, Vollenweider FX (2016): Phenomenology, Structure, and Dynamic of Psychedelic States, Curr. Topics Behav Neurosci 2016 Dec 27, doi:10.1007/7854_2017_477 [Epub ahead of print].

Kraehenmann R, Pokorny D, Vollenweider L; Preller KH, Pokorny T, Seifritz E, and Vollenweider FX (2016), The effects of LSD on mental imagery: implications for psychedelic-assisted psychotherapy, British Journal of Psychiatry; Psychopharmacology, submitted

Kometer M, Vollenweider FX (2016) Serotonergic Hallucinogen-Induced Visual Perceptual Alterations, Curr Top Behav Neurosci. 2016 Nov 30. DOI:10.1007/7854_2016_461 [Epub ahead of print]

Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX (2016): Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur. J. Neuropsychopharmacology, 26(4):756-766

Kraehenmann R., Schmidt A, Friston K, Preller KH, Seifritz E, and Vollenweider FX (2016): The mixed serotonin receptor agonist psilocybin reduces threat-induced modulation of amygdala connectivity. Neuroimage: Clinical 11, 53-60.

Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015): Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations. Psychopharmacology (Berl) 232: 3663-3676

Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller KH, Vollenweider FX, Brenneisen R, Muller F, Borgwardt S, Liechti ME (2015): Acute Effects of Lysergic Acid Diethylamide, Healthy Subjects. Biological Psychiatry 78: 544-553

Bernasconi F, Kometer M, Pokorny T, Seifritz E, Vollenweider FX (2015): The electrophysiological effects of the serotonin 1A receptor agonist buspirone in emotional face processing. European Journal of Neuropsychopharmacology 25: 474-482
Krähenmann R, Preller KH, Scheidegger M, Pokorny T, Bosch OG, Seifritz E, Vollenweider FX (2015): Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers. Biol Psychiatry. 78: 572-581
Csomor PA, Preller KH, Geyer MA, Studerus E, Huber T, Vollenweider FX (2014): Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry. Neuropsychopharmacology 39: 2485-2496

Bernasconi F, Schmidt A, Pokorny T, Kometer M, Seifritz E, Vollenweider FX (2014): Spatiotemporal Brain Dynamics of Emotional Face Processing Modulations Induced by the Serotonin 1A/2A Receptor Agonist Psilocybin. Cereb Cortex, 24(12):3221-31

Ort A, Kometer M, Rohde J, Seifritz E, Vollenweider FX (2014) The role of GABAB receptors in human reinforcement learning. Eur. J. Neuropsychopharmacology 24: 1606-1614

Kometer M, Schmidt A, Jäncke L, Vollenweider FX (2013): Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.  J Neurosci. 19; 33(25):10544-51.

Schmidt A, Kometer M, Bachmann R, Seifritz E, and Vollenweider FX (2013): The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacology (Berl); 225(1):227-39.

 Schmidt A, Diaconescu AO, Kometer M, Friston KJ, Stephan KE, Vollenweider FX (2013) Modeling Ketamine Effects on Synaptic Plasticity During the Mismatch Negativity. Cerebral Cortex 23(10):2394-406.

Kraehenmann R, Vollenweider FX, Seifritz E, Kometer M (2012) Crowding deficits in the visual periphery of schizophrenia patients. PLoS ONE; 7(9):e45884.

Studerus E, Gamma A, Kometer M, Vollenweider FX (2012): Prediction of psilocybin response in healthy volunteers, PLoS ONE;7(2):e30800.

Preller KH, Ingold N, Hulka LM, Vonmoos M, Jenni D, Baumgartner MR, Vollenweider FX, Quednow BB (2013): Increased Sensorimotor Gating in Recreational and Dependent Cocaine Users Is Modulated by Craving and Attention-Deficit/Hyperactivity Disorder Symptoms. Biol Psychiatry 73(3):225-34.

Holstein DH, Vollenweider FX, Geyer MA, Csomor PA, Belser N, Eich D (2013): Sensory and sensorimotor gating in adults suffering from attention-deficit/hyperactivity disorder (ADHD). Psychiatry Res 205(1-2):117-26.

Quednow BB, Kometer M, Geyer MA, Vollenweider FX (2012): Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology 37: 630-640.

Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX (2012): Mismatch Negativity Encoding of Prediction Errors Predicts S-ketamine-Induced Cognitive Impairments. Neuropsychopharmacology 37: 865-875

Kometer M, Bachmann R, Schmidt A, Seifritz E, Vollenweider FX (2012): Psilocybin biases facial recognition, goal-directed behavior, and mood state towards positive relative to negative emotions through different serotonergic subreceptors. Biol Psychiatry: 72 (11):898-906.

Quednow BB, Treyer V, Hasler F, Dörig N, Wyss MT, Burger C, Rentsch KM, Westera G, Schubiger PA, Buck A, Vollenweider FX (2011): Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. NeuroImage 59: 3922-3932.

Studerus E, Kometer M, Hasler F, Vollenweider FX (2011): Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J.Psychopharmacology 25: 1434-1452.

Kometer M, Cahn, BR, Andel D, Carter OL, Vollenweider FX (2011): The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biol. Psychiatry 69: 399-406

Holstein D H, Csomor PA, Geyer, MA, Hubert T, Brugger N, Vollenweider FX (2011): The effect of sertindole on sersory gating and cognition in healthy volunteers. J. Psychopharmacol.; 25(12):1600-13.

Hilti CC, Delko T, Orosz AT, Thomann K, Ludewig S, Geyer MA, Vollenweider FX, Feldon J, Cattapan-Ludewig K (2010): Sustained Attention and Planning Deficits but Intact Attentional Set-Shifting in Neuroleptic-Naive First-Episode Schizophrenia Patients. Neuropsychobiology 61: 79-86.

Holstein DH, Vollenweider FX, Jäncke L, Schopper C, Csomor PA (2010): P50 Suppression, Prepulse Inhibition, and Startle Reactivity in the Same Patient Cohort Suffering from Posttraumatic Stress Disorder. Journal of Affective Disorders 126(1-2): 188-197.

Roser P, Vollenweider FX, Kawohl W (2010): Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World Journal of Biological Psychiatry 11: 208-219.

Studerus E, Gamma A, Vollenweider FX (2010): Psychometric Evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE 5(8): e12412.

Vollenweider FX, Kometer M (2010): The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews Neuroscience 11: 642-651.

Csomor PA, Yee BK, Feldon J, Theodoridou A, Studerus E, Vollenweider FX (2009): Impaired prepulse inhibition and prepulse elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophrenia Bulletin 35: 244-255.

Hasler F, Kuznetsova OF, Krasikova RN, Cservenyak T, Quednow BB, Vollenweider FX, Ametamey SM, Westera G (2009): GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Appl. Radiat. Isot. 67: 598-601.

Hasler F, Studerus E, Lindner K, Ludewig S, Vollenweider FX (2009): Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology 23: 923-935.

Liechti ME, Hysek C, Vollenweider FX (2009): Interacting Cardiovascular Effects of Pindolol and MDMA (Ecstasy). Basic & Clinical Pharmacology & Toxicology (in press).

Quednow BB, Schmechtig A, Ettinger U, Petrovsky N, Collier DA, Vollenweider FX, Wagner M, Kumari V (2009): Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry 66: 614-620.

Cattapan-Ludewig K, Ludewig S, Messerli N, Vollenweider FX, Seitz A, Feldon J, Paulus MP (2008): Decision-making dysregulation in first-episode schizophrenia. J. Nerv. Ment. Dis. 196: 157-160.

Csomor PA, Stadler RR, Feldon J, Yee BK, Geyer MA, Vollenweider FX (2008): Haloperidol differentially modulates prepulse inhibition and P50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology 33: 497-512.

Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB (2008): On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav. Neurosci. 122: 885-900.

Geyer MA, Vollenweider FX (2008): Serotonin research: contributions to understanding psychoses. Trends Pharmacol.Sci. (TIPS) 29: 445-453.

Quednow BB, Csomor PA, Chmiel J, Beck T, Vollenweider FX (2008): Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. Int. J. Neuropsychopharmacol. 1-15.

Roser P, Vollenweider FX, Kawohl W (2008): Potential antipsychotic properties of central cannabinoid (CB(1)) receptor antagonists. World J. Biol. Psychiatry 1-12.

Wackermann J, Wittmann M, Hasler F, Vollenweider FX (2008): Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neurosci. Lett. 435: 51-55.

Carter OL, Hasler F, Pettigrew JD, Wallis GM, Liu GB, Vollenweider FX (2007): Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans. Psychopharmacology (Berl) 195: 415-424.

Vollenweider FX, Csomor PA., Knappe B, Geyer MA, Quednow BB (2007): The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology 32: 1876-1887.

Wittmann M, Carter O, Hasler F, Cahn BR, Grimberg U, Spring P, Hell D, Flohr H, Vollenweider FX (2007): Effects of psilocybin on time perception and temporal control of behaviour in humans. J. Psychopharmacol. 21: 50-64.

Csomor PA, Yee BK, Quednow BB, Stadler RR, Feldon R, Vollenweider FX (2006): The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. Behav. Brain Res. 174: 143-150.

Vollenweider FX, Barro M, Csomor PA and Feldon J (2006): Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels. Biol. Psychiatry 60: 597-603.

Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX (2005): Using psilocybin to investigate the relationship between attention, working memory and the serotonin1A&2A receptors. J Cognitive Neuroscience 17: 1497-1508.

Carter OL, Pettigrew JD, Hasler F, Wallis GM, Liu GB, Hell D, Vollenweider FX (2005): Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin. Neuropsychopharmacology 30: 1154-1162.

Cattapan-Ludewig K, Hilti CC, Ludewig S, Vollenweider FX, Feldon J (2005): Rapid visual information processing in schizophrenic patients: The impact of cognitive load and duration of stimulus presentation. Neuropsychobiology 52: 130-134.

Csomor PA, Vollenweider FX, Feldon J, Yee BK (2005): On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans. Behavioural Brain Research 162: 256-263.

Gamma A, Brandeis D, Brandeis R, Vollenweider FX (2005): The P3 in “ecstasy“ ploydrug users during response inhibition and execution. J.Psychopharmacology 19: 504-512.

Ludewig S, Geyer MA, Ramseier M, Vollenweider FX, Rechsteiner E, Ludewig K (2005): Information Processing Deficits and Cognitive dysfunctions in Panic Disorder. Journal of Psychiatry & Neuroscience 30(1): 37-43.

Vollenweider FX, Liechti M, Paulus MP (2005): MDMA affects both error-rate dependent and independent aspects of decision-making in two-choice prediction task.
J Psychopharmacology. 19: 366-374.

Carter O L,  Pettigrew J D, Burr D C, Alais D, Hasler F, Vollenweider FX (2004): Psilocybin impairs high-level but not low-level motion perception affects high-level but not low-level motion mechanisms in humans. NeuroReport 15:1947-1951.

Gamma A, Lehmann D, Frei E, Iwata K, Pascual-Marqui RD, Vollenweider FX (2004): Comparison of simultanously recorded [H215O]-Positron Emission Tomography (PET) and Low Resolution Brain Electromagnetic Tomography (LORETA) during cognitive and pharmacological activation. Human Brain Mapping 22:83-96.

Hasler F, Grimberg U, Benz M, Huber T, Vollenweider FX (2004): Acute psychological and physiological effects of psilocybin in healthy humans. A double-blind placebo-controlled dose-effect study. Psychopharmacology 172: 145-156.

Ludewig K, Geyer MA, Vollenweider FX (2003): Deficits in prepulse inhibition and habituation in never-medicated first-episode schizophrenia. Biol Psychiatry 54: 121-128.

Ludewig K, Ludewig S, Seitz A, Martina Obrist M, Geyer MA, Vollenweider FX (2003): The acoustic startle reflex and its modulation: Effects of age and gender in humans. Biol Psychology 63: 311-323.

Ludewig K, Paulus MP, Vollenweider FX (2003): Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients. Psychiatry Res 119: 293-306.

Ludewig S, Paulus MP, Ludewig K, Vollenweider FX (2003): Decision-making strategies by panic disorder subjects are more sensitive to errors. J Affective Disorders 76:183-189.

Umbricht D, Vollenweider FX, Schmid L, Grübel.C, Skrabo A, Huber T, Koller R (2003): Effects of the 5-HT2A Agonist Psilocybin on Mismatch Negativity Generation and AX-Continuous Performance Task: Implications for the Neuropharmacology of Cognitive Deficits in Schizophrenia. Neuropsychopharmacology 28: 170-181.

Hasler F, Bourquin D, Brenneisen R, Vollenweider FX (2002): Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man, J.Pharmaceutical and Biomedical Analysis 30: 331-339.

Leumann L, Feldon J, Vollenweider FX, Ludewig K (2002): Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenics. Biol Psychiatry 52: 729-739.

Ludewig K, Geyer MA, Etzensberger M, Vollenweider FX (2002): Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia. Schizophr Res 55: 129-137.

Ludewig K, Vollenweider FX (2002): Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome. SWISS MED WKLY 132:159-165.

Ludewig S, Ludewig K, Geyer MA, Hell D, Vollenweider FX (2002): Prepulse inhibition deficits in patients with panic disorder. Depression and Anxiety 15: 55-60.

Schönbächler RD, Gucker PM, Arigoni M, Kneifel S, Vollenweider FX, Buck A, Burger C, Berthold T, Brühlmeier M, Schubiger PA, Ametamey SM (2002): PET imaging of dopamine transporters in the human brain using [11C]-b-CPPIT, a cocaine derivative lacking the 2b-ester function. Nuc Med and Biol 29: 19-27.

Umbricht D, Koller R, Vollenweider FX, Schmid L (2002): Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 51: 400-406.

Frei E, Gamma A, Pascual-Marqui RD, Lehmann D, Hell D, Vollenweider FX (2001): Localization of MDMA-induced brain activity in healthy volunteers using Low Resolution Brain Electromagnetic Tomography (LORETA). Hum Brain Mapping 14: 152-165.

Gamma A, Buck A, Berthold T, Vollenweider FX (2001): No difference in brain activation during cognitive performance between Ecstasy (MDMA) user and controls: A [H215O]-PET study. J Clin Psychopharmacol 21:66-71.

Leumann L, Sterchi D, Vollenweider FX, Ludewig K, Früh H (2001): A real world neuronal network approch to the primary acoustic circuit and prepulse inhibition. Brain Res Bul, 56:101-10.

Liechti ME, Gamma A, Vollenweider FX (2001): Gender differences in the subjective effects of MDMA, Psychopharmacology 154:161-168.

Liechti ME, Geyer MA, Hell D, Vollenweider FX (2001): Effects of 3,4-Methylenedioxy-N-methylamphetamine (MDMA) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin. Neuropsychopharmacology 24:240-252.

Liechti ME, Vollenweider FX (2001): Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol Clin Exp 16: 589-598.

Vollenweider FX, Jones RT, Baggott MJ (2001): Caveat Emptor: Editors Beware, Neuropsychopharmacology 24: 461-463.

Buck A, Gucker P, Schönbächler R, Arigoni M, Kneifel S, Vollenweider FX, Ametamey S, Burger C (2000): Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: Assessement of methods. J Cereb Blood Flow Metab 20:253-262.

Gamma A, Buck A, Berthold T, Vollenweider FX (2000): Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by (H215O)-PET in healthy humans. Neuropsychopharmacology 23: 388-395.

Gamma A, Frei E, Lehmann D, Pascual-Marqui RD, Hell D, Vollenweider FX (2000): Mood state and brain electric activity in ecstasy users. NeuroReport 11:157-162.

Liechti ME, Baumann C, Gamma A, Vollenweider FX (2000): Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22:513-521.

Liechti ME, Saur M, Gamma A, Hell D, Vollenweider FX (2000): Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-405.

Liechti ME, Vollenweider FX (2000): Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans. Eur Neuropsychopharmaco, 10: 289-295.

Liechti ME, Vollenweider FX (2000): The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers. J. Psychopharmacology 14: 269-274.

Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC (2000): Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers. Arch. Gen. Psychiatry 57: 1139-1147.

Vollenweider FX, Vontobel P, Leenders KL, Hell D (2000): Effects of S-ketamine on striatal dopamine release: a [11C] raclopride PET study of a model psychosis in humans. J Psych Res 34:35-43.

Vollenweider FX, Gamma A, Liechti ME, Huber T (1999): Is a single dose MDMA harmless? Neuropsychopharmacology 21:598-600.

Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999): Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology 143:365-372.

Vollenweider FX, Vontobel P, Hell D, Leenders KL (1999): 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride. Neuropsychopharmacology 20:424-433.

Zessin J, Gucker P, Ametamey SM, Steinbach J, Brust P, Vollenweider FX, Johannsen B, Schubiger PA (1999): Efficient synthesis of enantiomerically pure thioesther precursors of [11C]McN-5652 from racemic McN-5652. J Label Comp and Radiopharm 42:1301-1312.

Ametamey S, Vollenweider FX, Patt J, Bourquin D, Hasler F, Beer HF, Schubiger PA (1998): 11C-Radiolabeling of hallucinogenic psilocin, a potential radioligand for studying the role of serotonin receptors in psychotic symptom formation. J Label Comp and Radiophar, 41:585-594.

Vollenweider FX (1998): Advances and pathophysiological models of hallucinogen drug actions in humans: a preamble to schizophrenia research. Pharmacopsychiat 31: 92-103.

Vollenweider FX, Antonini A, Leenders KL, Mathys K, Angst J (1998): Effects of high amphetamine doses on mood and cerebral glucose metabolism in normals using positron emission tomography (PET). Psychiatry Res Neuroimaging 83:149-162.

Vollenweider FX, Gamma A, Liechti ME, Huber T (1998): Psychological and cardiovascular effects and short-term sequelae of MDMA ("Ecstasy") on MDMA-naive healthy volunteers. Neuropsychopharmacology 19: 241-251.

Vollenweider FX, Vollenweider-Scherpenhuyzen MFI, Bäbler A, Vogel H, Hell D (1998): Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport 9:3897-3902.

Hasler F, Bourquin D, Brenneisen R, Bär T, Vollenweider FX (1997): Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72: 175-184.

Vollenweider FX, Antonini A, Leenders KL, Oye I, Hell D, Angst J (1997): Differential Psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers measured by FDG-PET. Eur Neuropsychopharmacol 7: 25-38.

Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997): Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372.

Vollenweider FX, Leenders KL, Scharfetter C, Antonini A, Maguire P, Missimer J, Angst J (1997): Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [F-18]-fluorodeoxyglocose (FDG). Eur Neuropsychopharmacol 7: 9-24.

Feng N, Vollenweider FX, Minder EI, Rentsch K, Grampp T, Vonderschmitt DJ (1995): Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples. Ther Drug Monit 17: 95-100.

Vollenweider FX (1992): The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis [Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose]. SUCHT 38: 389-409.

Do KQ, Vollenweider FX, Zollinger M, Cuénod M (1991): Effect of climbing fiber deprivation on the K+-evoked release of endogenous adenosine from rat cerebellar slices. Eur J Neurosci 3: 201-208.

Vollenweider FX, Do KQ, Cuénod M (1990): Effect of climbing fiber deprivation on release of endogenous aspartate, glutamate and homocysteate in slices of rat cerebellar hemispheres and vermis. J Neurochem 54: 1533-1540.


Refereed  reviews

Preller KH, Vollenweider FX (2016) Phenomenology, structure and dynamic of psychedelic states. In: Halberstadt AL, Nichols DE, Vollenweider FX (eds) Behavioral Neurobiology of Hallucinogens, Entactogens, and Psychotomimetics. Springer, pp 360-389, in press

Kometer M, Vollenweider FX (2016) Serotonergic hallucinogen-induced visual perceptual alterations. In: Halberstadt AL, Nichols DE, Vollenweider FX (eds) Behavioral Neurobiology of Hallucinogens, Entactogens, and Psychotomimetics . Springer, pp 300-320, in press

Geyer MA, Nichols DE, Vollenweider FX (2009): Serotonin-Related Psychedelic Drugs. In: Squire LR (ed) Encyclopedia of Neuroscience. Academic Press, Oxford, 741-748.

Vollenweider FX (2008): Multidimeensional approach to sensory gating functions and cognition in humans. In: Gustafson R., Eberhard J. (eds) The diagnostic concept of schizophrenia: via the laboratory to the clinic. Production Espri, 33-44.

Hasler  F, Grimberg U, Vollenweider FX (2005): Einfluss von Psilocybin auf psychologische, kardiovaskuläre, neuroendokrine und blutchemische Parameter. Suchtforschung des BAG, 2002-03 1:101-113.

Vollenweider FX, Vollenweider-Scherpenhuyzen M F I (2003): Halluzinogene, Amphetamine und Entactogene. Therapeutische Umschau 60: 323-328.

Hasler F, Vollenweider FX (2005): Untersuchung der Rolle des Serotonin-1A-Rezeptors im psychopharmakologischen Wirkungsprofil von MDMA beim Menschen. Suchtforschung des BAG, 2002-03 1:87-100.

Vollenweider FX (2002): Neurocognitive effects and brain mechanisms of MDMA in humans. In Drogodependencias: Marco Juridico y Cuestiones Biomédicas. II Seminario International de Toxicologia y Legislación Sanitaria. Eds: Felix Gomez-Gallego and Fernando Bandrés Moya. Libero de Ponencias Y Comunicaciones, 29-33.

Vollenweider FX, Liechti M, Gamma A, Greer G, Geyer MA (2002): Physiological and psychological effects of MDMA in humans. J.Psychoactive Drugs 34: 171-184.

Vollenweider FX, Ludewig S (2002): Neurocognitive effects of MDMA: A summary of controlled human studies. Adiktologie 1 (Supp): 47-52.

Vollenweider FX (2001): Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience 3: 265-279.

Vollenweider FX, Geyer MA (2001): A systems model of altered consciousness: Integrating natural and drug-induced psychoses. Brain Res Bull 56: 495-507.

Vollenweider FX, Geyer MA, Greer G (2001): Acute psychological and neurophysiological effects of MDMA in humans. Heffter Review Psych Res 2: 53-63.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (2000): Emergency cases in drug abuse [Notfälle bei Drogenmissbrauch]. Der Internist 41: 886-898.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (1999): Notfälle bei Drogenmissbrauch. Notfall & Rettungsmedizin 2: 518-531.

Vollenweider-Scherpenhuyzen MFI, Vollenweider FX (1998): Der Drogennotfall. Anaesthesist 47: 946-955.

Vollenweider FX (1997): MDMA-Forschungen am Menschen: Strategien und erste Ergebnisse. SUCHT, 35-43.

Vollenweider FX (1995): Positronen-Emissions-Tomographie (PET): Klinische Bedeutung und Perspektiven für die Psychiatrie. Nuclearmediziner 5: 309-317.

Vollenweider FX (1992): The use of psychotomimetics in schizophrenia research with special emphasis on the PCP/ketamine model psychosis [Die Anwendung von Psychotomimetika in der Schizophrenieforschung unter besonderer Berücksichtigung der Ketamin/PCP-Modell-Psychose]. SUCHT 38: 389-409.

Cuénod M, Audinat E, Do KQ, Gähwiler BH, Grandes P, Herrling P, Knöpfel T, Perschak H, Streit P, Vollenweider FX, Wieser HG (1990): Homocysteic acid as transmitter candidate in the mammalian brain and excitatory amino acids in epilepsy. Adv Exp Med Biol 268: 57-63.

Book contributions/proceedings

Behavioral Neurobiology of Psychedelic Drugs (2018). Series: Current Topics in Behavioral Neurosciences (Vol. 36). Halberstadt, Adam, Vollenweider, Franz X., Nichols, David E. (Eds.) Springer, Berlin, Heidelberg. eBook ISBN 978-3-662-55880-5

Vollenweider FX, Preller KH (2018): Neurobiologische Grundlagen der Wirkung von Psychedelika (423-436). In: von Heyden M., Jungaberle H., Majić T. (eds) Handbuch Psychoaktive Substanzen.Springer Reference Psychologie. Springer, Berlin, Heidelberg.; Online ISBN 978-3-642-55125-3

Vollenweider FX (2008): Struktur und Neurobiologie der Halluzinogenerfahrung. In J. Jungaberle, P. Gasser, J. Weinhold & R. Verres (Eds.), Therapie mit psychoaktiven Substanzen. Praxis und Kritik der Psychotherapie mit LSD, Psilocybin und MDMA, Bern, Huber Verlag, 111-130.

Vollenweider MFI, Vollenweider FX (2004): Halluzinogene. Suchtberung in der Apotheke. Fahrmbacher-Lutz C. (Ed), Deutscher Apotheker Verlag Stuttgard, 200-218.

Gamma A, Lehmann D, Frei E, Pascual-Marqui RD, Vollenweider FX (2002): The relationship between co-recorded [H215O]-PET and EEG functional tomography (LORETA) before and during pharmacological activation, Excerpta Medica International Congress Series, 1232 (2002) 247-251.

Vollenweider FX, Ludewig K, Vollenweider MFI (2002): Schizophrenie – Auf der Spur eines Rätsels. Gehirn und Geist, Spektrum der Wissenschaft, 4: 36-42.

Gamma A., Liechti ME, Vollenweider FX (2001): Giving MDMA to Human Volunteers in Switzerland. In Holland, J (Ed.), Ecstasy: The complete guide. Rochester, Park Street Press, 327-337.

Vollenweider FX (2001): Vom Zauberpilz zur Hirnforschung, unijournal Universität Zürich, 1: 7.

Vollenweider FX (2000): Halluzinogene und Gehirn: Beeinflussung der Hirnaktivität durch Halluzinogene. In Georg-Friedrich-Götz Stiftung (Ed.), Festschrift aus Anlass der Verleihung des Georg-Friederich-Götz-Preises Medizinische Fakultät der Universität Zürich, 2000, 51-75.

Vollenweider FX, Frei E, Gamma A (2000): Lokalisation MDMA-induzierter hirnelektrischer Aktivität bei gesunden Probanden mittels Low Resolution Brain Electromagnetic Tomoraphy (LORETA). In Rihs-Middle M (ed), Suchtforschung des BAG. Bern, BAG, 6-14.

Vollenweider FX, Gamma A, Vollenweider-Scherpenhuyzen MFI (1999): Neuronal correlates of hallucinogen-induced altered states of consciousness. In Hameroff SR, Kaszniak AW, Chalmers DJ (eds), Towards a Science of Consciousness. The Third Tucson Discussion and Debates. Cambridge, MIT Press, 99-109.

Vollenweider FX (1998): Beziehung zwischen Hirnaktivitätsmustern (PET) und Dimensionen veränderter Bewusstseinszustände. In Verres R, Leuner H, Dittrich A (eds), Welten des Bewusstseins. Multidisziplinäre  Entwürfe. 1 Berlin, Verlag für Wissenschaft und Bildung (VWB), 111-126.

Vollenweider FX (1998): Neue Aspekte der PET-und SPECT-Forschung: Metabolische Korrelate psychotischer Störungen bei Schizophrenen und Modell-Psychosen. In Hinterhuber H, Fleischhacker WW (eds), Biologische Grundlagen der Schizophrenien. 1 140-160.

Vollenweider FX (1998): Recent advances and concepts in the search for biological correlates of hallucinogen-induced altered states of consciousness. The Heffter Review Psych Res, 1: 21-32.

Vollenweider FX (1996): Perspektiven der Bewusstseinsforschung mit Halluzinogenen. In Liggenstorfer R, Rätsch C (eds), Maria Sabina - Botin der heiligen Pilze. Vom traditionellen Schamanentum zur weltweiten Pilzkultur. 1 Freiburg, Nachtschattenverlag, 203-210.

Vollenweider FX (1994): Evidence for a cortical-subcortical dysbalance of sensory information processing during altered states of consciousness using PET and FDG. In Pletscher A, Ladewig D (eds), 50 Years of LSD: State of the Art and Perspectives of Hallucinogens. 1 London, Parthenon Publishing, 67-86.

Vollenweider FX (1994): Kortiko-Subkortikale Dysbalance während Ketamin- und Psilocybin- induzierten Bewusstseinszuständen. In Dittrich A, Hofmann A, Leuner H (eds), Welten des Bewusstseins. Band 3: Experimentelle Psychologie, Neurobiologie und Chemie. 1 Berlin, VWB - Verlag für Wissenschaft und Bildung, 25-43.

Vollenweider FX, Leenders KL, Angst J (1994): Hyperfrontalität während Ketamin- und Psilocybin-induzierten Modell-Psychosen: Eine PET-Studie mit gesunden Probanden. In Peters UH, Schifferdecker M, Krahl A (eds), 150 Jahre Psychiatrie. Eine vielgestaltige Psychiatrie für die Welt von Morgen. Köln, Martini-Verlag, 479-484.

Vollenweider FX, Antonini A, Scharfetter C, Angst J, Leenders KL (1993): Zerebraler Energiemetabolismus während akut induzierter Ketamin-Modell-Psychose bei gesunden Probanden, gemessen mittels PET (Positronen-Emissions-Tomographie) und [18F]-Fluorodeoxyglukose. In Baumann P (ed), Biologische Psychiatrie der Gegenwart. 1 Wien, Springer-Verlag, 497-499.

Vollenweider FX, Vollenweider MFI (1993): Halluzinogene: Eine Droge berauscht die Wissenschaft. Psychologie Heute 5: 30-36.

Vollenweider FX (1992): Der Einsatz von PET (Positronen-Emissions-Tomographie) zum Studium neuronaler Aktivität während veränderter Bewusstseinszustände. In Leuner H, Schlichting M (eds), Jahrbuch des Europäischen Collegiums für Bewusstseinsstudien 1992. 1 Berlin, VWB - Verlag für Wissenschaft und Bildung, 33-52.

Cuénod M, Do KQ, Vollenweider FX, Klein A, Streit P (1988): The puzzle of the transmitters in the climbing fibers. In Strata P (ed), Experimental Brain Research Series (Symposium on "The olivocerebellar system in motor control"). Springer, Berlin.

Streit P, Do KQ, Vollenweider FX, Grandes P, Liu C-J, Matute C, Cuénod M (1988): Localisation and Release of Excitatory Amino Acids. In AnonymousFrontiers in Excitatory Amino Acid Research. Alan R. Liss, Inc., 101-108.